FLASCO is pleased to share a new white paper exploring the transformative potential of bispecific antibodies (BsAbs) in lymphoma treatment. Developed by thought leaders from across Florida, the paper offers actionable recommendations for wider adoption across Florida. With demonstrated success in clinical trials, BsAbs represent a significant advancement in cancer care.

The report highlights the importance of collaboration between academic institutions and community oncology centers to streamline access and ensure patients receive high-quality care closer to home. It provides practical guidance on treatment management, identifying and managing side effects, and supporting outpatient care.

Oncology professionals are encouraged to explore the findings and implement best practices to enhance patient outcomes. FLASCO extends its gratitude to the authors and contributors whose expertise and dedication made this white paper possible.

FLASCO Proudly Announces the Release of a New White Paper Providing Practical Guidance on Expanding Access to Innovative Cancer Therapies